Amphista Therapeutics has unveiled promising pre-clinical data on their SMARCA2 and TEAD Targeted Glue™ programs at the AACR Annual Meeting, highlighting the potential of their non-cereblon/non-VHL targeted degraders. The data demonstrate robust selectivity for SMARCA2 over SMARCA4, with significant in vivo degradation following oral administration, translating into the suppression of downstream biomarkers such as KRT80 and PLAU. This achievement underscores the therapeutic relevance of their approach, leveraging insights from high-resolution cryo-electron microscopy to optimize degradation efficacy and selectivity.

The TEAD program also showcased notable findings, with oral in vivo tumor regression observed following intermittent dosing. The FBXO22-dependent TEAD degraders exhibited anti-proliferative activity in mesothelioma cell lines and synergistic effects with osimertinib in an EGFR-mutant NSCLC model. The systematic optimization detailed in their bioRxiv publication highlights the enhanced degradation potency and kinetics of these early TEAD Targeted Glues™, establishing a promising therapeutic avenue for Hippo pathway-driven cancers.

These developments position Amphista’s programs as potential game-changers in targeted protein degradation strategies, particularly for cancers resistant to conventional therapies. The promising preclinical results not only pave the way for candidate selection later this year but also encourage collaborations that could accelerate the transition of these innovative therapies into clinical settings. This shift in focus towards degradation-based modalities could significantly impact drug development timelines and strategies in the oncology landscape, particularly for challenging tumor types.

Source: globenewswire.com